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Abstract
Polyunsaturated fatty acids (PUFA) have a role in many physiological processes, including energy production, modulation of
inflammation, and maintenance of cell membrane integrity. High plasma PUFA concentrations have been shown to have
beneficial effects on cardiovascular disease and mortality. To identify genetic contributors of plasma PUFA concentrations,
we conducted a genome-wide association study of plasma levels of six omega-3 and omega-6 fatty acids in 1,075
participants in the InCHIANTI study on aging. The strongest evidence for association was observed in a region of
chromosome 11 that encodes three fatty acid desaturases (FADS1, FADS2, FADS3). The SNP with the most significant
association was rs174537 near FADS1 in the analysis of arachidonic acid (AA; p=5.95610
246). Minor allele homozygotes had
lower AA compared to the major allele homozygotes and rs174537 accounted for 18.6% of the additive variance in AA
concentrations. This SNP was also associated with levels of eicosadienoic acid (EDA; p=6.78610
29) and eicosapentanoic
acid (EPA; p=1.07610
214). Participants carrying the allele associated with higher AA, EDA, and EPA also had higher low-
density lipoprotein (LDL-C) and total cholesterol levels. Outside the FADS gene cluster, the strongest region of association
mapped to chromosome 6 in the region encoding an elongase of very long fatty acids 2 (ELOVL2). In this region, association
was observed with EPA (rs953413; p=1.1610
26). The effects of rs174537 were confirmed in an independent sample of 1,076
subjects participating in the GOLDN study. The ELOVL2 SNP was associated with docosapentanoic and DHA but not with
EPA in GOLDN. These findings show that polymorphisms of genes encoding enzymes in the metabolism of PUFA contribute
to plasma concentrations of fatty acids.
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Introduction
Polyunsaturated fatty acids (PUFA) refer to the class of fatty
acids with multiple desaturations in the aliphatic tail. Short chain
PUFA (up to 16 carbons) are synthesized endogenously by fatty
acid synthase. Long chain PUFA are fatty acids of 18 carbons or
more in length with two or more double bonds. Depending on the
position of the first double bond proximate to the methyl end,
PUFA are classified as n-6 or n-3. Long chain PUFA are either
directly absorbed from food or synthesized from the two essential
fatty acids linoleic acid (LA; 18:2n-6) and alpha-linolenic acid
(ALA; 18:3n-3) through a series of desaturation and elongation
processes [1]. The initial step in PUFA biosynthesis is the
desaturation of ALA and LA by the enzyme d6-desaturase
(FADS2; GeneID 9415) (Figure 1). PUFA modulate inflammatory
response through a number of different mechanisms including
modulation of cyclooxygenase and lipoxigenase activity [2].
Cyclooxygenase and lipoxigenase are essential for production of
eicosanoids and resolvins [2–4]. Since n-3 and n-6 fatty acids
compete for the same metabolic pathway and produce eicosanoids
with differing effects, it has been theorized that the balance of the
two classes of PUFA may be important in the pathogenesis of
inflammatory diseases.
Epidemiological studies have shown that fatty acid consumption
and plasma levels, in particular of the n-3 family, are associated
with reduced risk of cardiovascular disease [5–7], diabetes [8–10],
depression [11,12], and dementia [13]. However, not all studies
show significant associations and there has been inconsistencies in
the direction of the associations especially for the n-6 acids [14,15].
The different methods (dietary questionnaire or biomarkers) for
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18]. The disadvantage of using dietary PUFA intake is the
evidence of inaccuracies intrinsic in any reporting methods of
dietary intake that plasma levels would circumvent. In addition,
direct measures of PUFA reflect the cumulative effects of intake
and endogenous metabolism. Dietary fatty acids can be converted
into longer chain PUFA or stored for energy thus another reason
for inconsistent results may be due the general lack of control for
individual differences in metabolism once fatty acids are
consumed.
Previous studies have examined the association of genetic
variants, especially polymorphisms in the FADS genes, on fatty
acid concentrations in plasma and erythrocyte membranes [19–
21]. There are 3 FADS (FADS1 [GeneID 3992] ,FADS2, and
FADS3 [GeneID 3992]) clustered on chromosome 11. Variants in
FADS1 and FADS2 have been consistently shown to be associated
with PUFA concentrations. It is unknown whether other loci also
determine fatty acid concentrations. To address this question, we
conducted a genome-wide association study of plasma fatty acid
concentration in participants in the InCHIANTI study.
Results
Linoleic acid (LA) constituted the highest proportion of total
fatty acids followed by arachidonic acid (AA) (Table 1) The narrow
heritability was highest for AA (37.7%) followed by LA (35.9%),
eicosadienoic acid (EDA, 33.3%), alpha-linolenic acid (ALA,
28.1%), eicosapentanoic acid (EPA, 24.4%), and docosahexanoic
acid (DHA,12.0%). For EDA, AA, and EPA, genome-wide
significant signals fell in the FADS1/FADS2/FADS3 region on
chromosome 11 (Figure 2, Figure 3, Table S1). Of these, the most
significant SNP was rs174537 for AA (P=5.95610
246), where the
variant explained 18.6% of the additive variance of AA
concentrations. This SNP was significantly associated with EDA
(P=6.78610
29), and EPA (P=1.04610
214). The association with
LA (P=5.58610
27) and ALA (P=2.76610
25) did not reach
genome-wide significance, and there was no association with DHA
(P=0.3188). Presence of the minor allele (T) was associated with
lower concentrations of longer chain fatty acids (EDA, AA, EPA),
but with higher concentrations of LA and ALA (Table 2). With the
exception of DHA, the SNPs exhibiting the strongest evidence of
association with the fatty acids examined in this study mapped to
the FADS1, FADS2, and FADS3 cluster. The most significant SNP
for DHA was on chromosome 12 within the SLC26A10 gene
(GeneID 65012, rs2277324; PDHA=2.65610
29). In all cases,
inclusion of the most significant SNP as a covariate in the model
resulted in attenuation of the effect of the other SNPs in the region
(Figure S1). Accordingly, associated SNPs in this region were in
significant linkage disequilibrium with each other in the In-
CHIANTI sample (Figure S2).
To investigate whether this SNP has an effect on other
cardiovascular disease risk factors, we examined the association
of rs174537 with plasma lipid parameters. Significant association
was observed with total cholesterol (P=0.027) and LDL-
cholesterol (P=0.011), but not with either HDL-C (P=0.775) or
triglycerides (P=0.862; Table 2). The minor allele homozygotes
(TT) had 8 mg/dL lower total cholesterol and 9 mg/dL lower
LDL-C compared with GG subjects.
Figure 1. The metabolic pathway of n-3 and n-6 fatty acids. The fatty acids examined in the study are indicated in bold. The dashed arrows
indicate pathways absent in mammals.
doi:10.1371/journal.pgen.1000338.g001
Author Summary
Polyunsaturated fatty acids (PUFA) have a number of
beneficial effects on human health. Plasma PUFA concen-
trations are determined by a combination of dietary intake
and metabolic efficiency. To determine the genes involved
in PUFA homeostasis, we scanned the genome for genetic
variations associated with plasma PUFA concentrations.
The fatty acid desaturase gene, studied in previous
candidate gene association studies, was the strongest
determinant of plasma PUFA. A second gene encoding a
fatty acid elongase was associated with long chain PUFA.
The results of this study contribute to our understanding
of the genetics of PUFA homeostasis. These genetic
markers may be useful tools to examine the inter-
relationship between diet, genetics, and disease.
Genome-Wide Association of PUFA
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fatty acid concentrations beyond the FADS cluster, we examined the
top 3 non-redundant (r2,0.2) SNPs from the analysis of each fatty
acid and selected the SNPs that mapped to candidate gene regions
(defined as 20kb upstream of intron 1, or downstream of last exon)
for replication in an independent study (Table S1). These included
rs16940765 (HRH4 [GeneID 59340], chr18, PEDA=2.18610
26),
rs17718324 (SPARC [GeneID 6678], chr5, PAA=7.64610
27)a n d
rs953413 (ELOVL2 [GeneID 54898], chr6, PAA=1.1610
26). In the
InCHIANTI study, these four SNPs most strongly associated with a
specific fatty acid, unlike FADS cluster that was associated with
multiple fatty acids. We noted, however that rs16940765 (HRH4),
rs953413 (ELOVL2) and rs2277324 (SLC26A10) showed significant
association at the 0.05 level for AA (P=0.003), DHA (0.004), and
EPA (P=0.004) respectively. In addition, there were four SNPs
(rs953413, rs1570069, rs3798719, rs7744440) in the ELOVL2 gene
were associated with EPA with p values ranging from 9.51610
25 to
1.10610
26 (Figure S3). In total, 5 SNPs (rs174537, rs2277324,
rs16940765, rs17718324, rs953413) were selected for replication.
In the GOLDN study, there were significant associations of
FADS SNP, rs174537, with ALA, LA, AA, EPA and DHA
(P,0.001) and marginal association with docosapentaenoic acid
(DPA) (P=0.068) (Table 2). As with the InCHIANTI study,
presence of the T allele was associated with higher ALA and LA
concentration and lower AA, EPA, DPA and DHA concentra-
tions. Consistent with the InCHIANTI study, this SNP was
associated with total cholesterol and LDL-C but not triglycerides
or HDL-C. We also observed strong associations of rs953413 with
docosapentanoic acid (DPA; P=0.002) and DHA (P,0.001). The
presence of the minor allele (A) was associated with lower DHA
and higher DPA and higher AA compared to the minor allele
carriers (Table 2). The remaining 3 SNP (rs2277324, rs16940765,
rs17718324) were not associated with fatty acid concentrations in
the GOLDN study (data not shown).
Discussion
The genome-wide association approach enables comprehensive
examination of the genome to identify novel loci contributing to
PUFA homeostasis. In addition, the significance of the genes
previously reported in association with PUFA can be assessed
relative to other regions in the genome. Here, we demonstrated
that polymorphisms in the FADS cluster are the strongest
determinants of plasma and erythrocyte fatty acid concentrations,
explaining up to 18.6% of the additive variance in plasma AA
levels. Consistent with prior reports, the greatest evidence of
association was observed in the region containing FADS1, FEN1
(flap structure specific endonuclease, GeneID 2237), two hypo-
thetical proteins (C11orf9 [GeneID 745], C11orf10 [GeneID 746]),
and the promoter region of FADS2 [20,21]. With the exception of
EDA, the direction of the association of rs174537 with plasma and
erythrocyte fatty acids is consistent with previous reports. We find
that there are higher levels of ALA and LA which is suggestive of
an accumulation of the initial products of the PUFA metabolic
pathway. The cluster of SNP ranging from rs174537 to rs509360
showed the strongest evidence for association, and contains the
haplotype block previously examined in relation to plasma and
erythrocyte fatty acids [20,21]. Based on the HapMap CEU data,
the r2 between rs174537 and previously reported SNPs were
$0.8. If functional polymorphisms exist within this region, it could
affect the expression of both desaturases. To this end, in a recent
report of genome-wide association of global gene expression, the
rs174546 that is in LD with the rs174537 (r
2=0.99) was associated
with FADS1 expression (LOD=5, P=1.6610
26) but not FADS2
(LOD=0.7, P=0.07) in lymphoblastoid cells [22,23]. The allele
associated with higher AA showed greater expression of FADS1,
consistent with our results. Since FADS1 and FADS2expression
varies by tissue type, it would be of interest to examine the effect of
the variant on gene expression in other cell types [24].
The T allele associated with lower AA was also associated with
decreased LDL-C and total cholesterol. The association with
LDL-C was also observed in a large meta-analysis of plasma lipid
concentrations in ,8500 subjects [25,26]. In this meta-analysis,
there was stronger evidence of association with high density
lipoprotein (HDL-C) and triglycerides (TG), where the T allele
displayed lower HDL-C and higher triglyceride concentrations.
Finally, in the Welcome Trust Case-Control Consortium coronary
artery disease (CAD) study, the T allele was associated with
increased prevalence of CAD (P=0.0375) [27]. The increased
prevalence of CAD, low HDL-C and high TG is consistent with
lower AA concentrations in the T allele carriers. Endogenous
PUFA are natural ligands of peroxisome proliferator activating
receptor alpha (PPARA) [28]. PPARA activation has been shown
to elevate HDL-C and lower TG by inducing the expression of
ApoA1, Apo-AII, lipoprotein lipase and suppressing ApoCIII [29–
32]. Thus the low AA, EPA and EDA in the T allele carriers will
results in lower PPARA activation. Under this hypothesis, we
would expect the T allele carriers to display higher LDL-C since
PPARA is known to enhance LDL-C clearance [33] . However, in
both the InCHIANTI and GOLDN study, lower concentrations
of LDL-C are observed. It is likely that there are other
mechanisms by which fatty acids regulate lipoprotein homeostasis,
for example through membrane fluidity. It may be possible, that
the higher concentrations of linoleic and linolenic acid in the T
allele carriers results in increased membrane fluidity, thus
increasing LDL-receptor recycling leading to lower LDL-C.
The elongation of very long chain fatty acid (ELOVL) family
genes are elongases that catalyze the rate-limiting condensation
reaction resulting in the synthesis of very long chain fatty acids
Table 1. Descriptive Characteristics of InCHIANTI and GOLDN
study.
Trait INCHIANTI GOLDN
N (m/f) 1075 (485/590) 1076 (519/557)
Age (years) 68.37 (15.5) 48.4 (16.4)
BMI (kg/m2) 27.12 (4.1) 28.3 (5.6)
Total Cholesterol (mg/dL) 213.62 (40.7) 190.1 (38.9)
HDL Cholesterol (mg/dL) 55.98 (15.1) 47 (13.1)
LDL Cholesterol (mg/dL) 133.08 (35.3) 121 (31.3)
Triglyceride (mg/dL) 122.79 (65.1) 139.2 (117.3)
Glucose (mg/dl) 94.23 (26.2) 101.6 (19.0)
Linoleic Acid
a 24.8 (4.0) 12.9 (1.4)
Linolenic Acid
a 0.4 (0.3) 0.1 (0.0)
Eicosadienoic Acid
a 0.1 (0.1) N/A
Arachidonic Acid
a 8.0 (1.9) 13.6 (1.2)
Eicosapentanoic Acid
a 0.61 (0.2) 0.5 (0.3)
Docosahexanoic Acid
a 2.29 (0.8) 3.0 (0.9)
Total energy , kal/day 2000 (596) 2122 (1190)
Dietary fat, % energy 30.9 (5.1) 35.4 (6.9)
Values represent mean (SD).
aFatty acids are plasma concentrations (% total fatty acids) for InCHIANTI and
erythrocytes concentration for GOLDN.
doi:10.1371/journal.pgen.1000338.t001
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The ELOVL1, 3 and 6 are involved in synthesis of monounsat-
urated and saturated long chain fatty acids while ELOVL2, 4 and
5 elongate polyunsaturated fatty acids [35]. In this study, rs953413
in the ELOVL2 was the third most significant SNP in the analysis
of EPA, with strong, although not genome-wide level significant
association with long chain fatty acids EPA and DHA. In
GOLDN, there were no significant associations of this SNP with
EPA, but a significant association was observed with DPA. In
mammals, two elongation steps are required for the synthesis of
DHA from EPA. First, EPA is elongated to DPA, then to 24:5n-3
followed by a desaturation and retroconversion step to form DHA
[1] (Figure 1). The two initial elongation steps of 20 and 22-C fatty
acids are mediated by ELOVL2 [36]. The rs953413 is associated
with substrate EPA (InCHIANTI), and product DPA (GOLDN)
and DHA (both studies) of the EVOLV2 pathway. Plasma DPA
levels were not measured in InCHIANTI, thus whether this
association is also observed in this population cannot be
investigated. Why the ELOVL2 SNP was not associated with
EPA in GOLDN is not clear, however it may reflect the
differences in fatty acid metabolism in erythrocytes versus plasma
as they reflect two slightly different pools of fatty acids [37]. Plasma
fatty acids reflect short term intake of fatty acids whereas
erythrocyte levels reflect long term intake. Thus the different
results between the plasma and erythrocyte fatty acids may reflect
dietary differences between subjects in the GOLDN (USA) and the
InCHIANTI study (Italy). Regardless of these differences, the
results of this study suggestive of the role of ELOVL2 in the
conversion of EPA to DHA in humans. The presence of the minor
(A) allele was associated with higher EPA/DPA and lower DHA. If
rs953413, located in intron 1, is the functional SNP (or is in LD
with the functional SNP), this variant would likely be associated
with lower expression of the ELOVL2 or result in a less efficient
variant of the elongase resulting in decreased elongation of EPA to
DHA. In lymphoblastoid cells, this SNP was not associated with
ELOVL2 expression (LOD=0.4, P=0.2) [22,23]. Further inves-
tigation in other cell lines and functional analysis of the different
variants is warranted.
In summary, we have shown that the major loci for fatty acid
concentrations in both plasma and erythrocyte membranes are in
Figure 2. Genome-wide scans of omega-6 fatty acid profiles in InCHIANTI study. Genome-wide associations of plasma linoleic acid (A),
eicasadienoic acids (B) and arachidonic acid (C) with 495,343 autosomal and X chromosome SNPs that passed quality control graphed by
chromosome position and 2log10 p-value. The most significant variant was within the FAD1/FAD2/FAD3 cluster on chromosome 11. The genes
nearby or within the SNPs that were selected for replication in GOLDN are indicated.
doi:10.1371/journal.pgen.1000338.g002
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chromosome 11 was the major contributor of plasma fatty acid
concentrations, and thus may have implications for cardiovascular
disease. In addition, we have identified a second promising locus in
ELOVL2 that is involved in the homeostasis of longer chain n-3
fatty acids. Future studies should investigate the interactions
between dietary intake, circulating levels of fatty acids and genetic
variants on risk of diseases such as cardiovascular disease.
Material and Methods
Sample Description
The InCHIANTI study is a population-based epidemiological
study aimed at evaluating factors that influence mobility in the
older population living in the Chianti region of Tuscany, Italy.
Details of the study have been previously reported [38]. Briefly,
1616 residents were selected from the population registry of Greve
in Chianti (a rural area: 11 709 residents with 19.3% of the
population greater than 65 years of age) and Bagno a Ripoli
(Antella village near Florence; 4704 inhabitants, with 20.3%
greater than 65 years of age). The participation rate was 90%
(n=1453) and participants ranged between 21–102 years of age.
Overnight fasted blood samples were collected for genomic DNA
extraction and measurement of plasma fatty acids. Genotyping
was completed for 1231 subjects using the Illumina Infinium
HumanHap 550 genotyping chip (ver1 and ver3 chips were used).
The study protocol was approved by the Italian National Institute
of Research and Care of Aging Institutional Review.
There were 85 parent-offspring pairs, 6 sib-pairs and 2 half-
sibling pairs documented. We investigated any further familial
relationships using IBD of 10,000 random SNPs using RELPAIR
and uncovered 1 parent-offspring, 79 siblings and 13 half-sibling
[39]. We utilized the correct family structure inferred from genetic
data for all analyses. In addition, we identified 2 duplicated
samples and removed these from the study. Sample quality was
assessed using the GAINQC program (http://www.sph.umich.
edu/csg/abecasis/GainQC/). The average genotype complete-
ness and heterozygosity rates were 98% and 32% respectively. We
excluded subjects that had less than 97% of genotyped
completeness (n=12), heterozygosity rate of less than 30%
Figure 3. Genome-wide scans of omega-3 fatty acid profiles in InCHIANTI study. Genome-wide associations of plasma alpha linolenic acid
(A), eicosapentanoic acid (B) and docasahexanoic acid (C) with 495,343 autosomal and X chromosome SNPs that passed quality control graphed by
chromosome position and 2log10 p-value. The most significant variant was within the FAD1/FAD2/FAD3 cluster on chromosome 11. The genes
nearby or within the SNPs that were selected for replication in GOLDN are indicated.
doi:10.1371/journal.pgen.1000338.g003
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chromosome SNPs (n=1). The final sample size used for SNP
quality control was 1210.
The confirmation study population consisted of 1120 white men
and women in the United States participating in the Genetics of
Lipid Lowering Drugs and Diet Network (GOLDN) Study. The
majority of participants were re-recruited from the ongoing
National Heart and Lung and Blood Institutes (NHLBI) Family
Heart Study (FHS) [40] in two genetically homogeneous centers
(Minneapolis, MN and Salt Lake City, UT). GOLDN is part of the
Program for Genetic Interactions (PROGENI) Network, a group
of NIH-funded intervention studies of gene-environmental inter-
actions. The primary aim of the GOLDN study was to
characterize the genetic components of triglycerides response
following a high fat meal and hypolipedemic drug, fenofibrate.
Detailed study design and methodology has been previously
described [41,42]
In the replication sample, we excluded persons with missing
genotypes or extreme fatty acid values. The final data set consists
of information on 1076 individuals. The protocol for this study was
approved by the Human Studies Committee of Institutional
Review Board at University of Minnesota, University of Utah and
Tufts University/New England Medical Center. Written informed
consent was obtained from all participants.
Biochemical Measurements
InCHIANTI: Plasma fatty acid measurement methods has been
described previously [43]. Briefly, blood samples were collected in
the morning after a 12-hr overnight fast. Aliquots of plasma were
immediately obtained and stored at 280 C. Fatty acid methyl
esters (FAME) were prepared through transesterification using
Lepage and Roy’s method with modification [44,45]. Separation
of FAME was carried out on an HP-6890 gas chromatograph
(Hewlett- Packard, Palo Alto, CA) with a 30-m fused silica column
(HP-225; Hewlett-Packard). FAMEs were identified by compar-
ison with pure standards (NU Chek Prep, Inc., Elysian, MA). For
quantitative analysis of fatty acids as methyl esters, calibration
curves for FAME (ranging from C14:0 to C24:1) were prepared by
adding six increasing amounts of individual FAME standards to
the same amount of internal standard (C17:0; 50xg). The
correlation coefficients for the calibration curves of fatty acids
were in all cases higher than 0.998 in the range of concentrations
studied. Fatty acid concentration was expressed as a percentage of
total fatty acids. The coefficient of variation for all fatty acids was
on average 1.6% for intraassay and 3.3% for interassay. HDL-C,
total cholesterol and triglycerides were determined using com-
mercial enzymatic tests (Roche Diagnostics, Mannheim, Ger-
many). Serum low-density lipoprotein cholesterol (LDL-C) was
computed with the Friedewald formula (LDL-C=total cholesterol
2 HDL-C 2 triglicerides/5).
GOLDN: Fatty acids (FA) in erythrocyte membrane were
measured following procedures described previously [46] Briefly,
lipids were extracted from the erythrocyte membranes with a
mixture of chloroform:methanol (2:1, v/v), collected in heptanes
and injected onto a capillary Varian CP7420 100-m column with
a Hewlett Packard 5890 gas chromatograph (GC) equipped with a
HP6890A autosampler. The GC was configured for a single
capillary column with a flame ionization detector and interfaced
with HP chemstation software. The initial temperature of 190uC
was increased to 240uC over 50 minutes. Fatty acid methylesters
from 12:0 through 24:1n9 were separated, identified and
expressed as percent of total fatty acid. Triglycerides were
measured using a glycerol blanked enzymatic method (Trig/GB,
Roche Diagnostics Corporation, Indianapolis, IN) and cholesterol
was measured using a cholesterol esterase, cholesterol oxidase
reaction (Chol R1, Roche Diagnostics Corporation) on the
Roche/Hitachi 911 Automatic Analyzer (Roche Diagnostics
Corporation). For HDL-cholesterol, the non-HDL-cholesterol
was first precipitated with magnesium/dextran. LDL-cholesterol
was measured by a homogeneous direct method (LDL Direct
Liquid Select Cholesterol Reagent, Equal Diagnostics, Exton,
PA).
Table 2. Associations of fatty acids and plasma lipids by rs174537 (FADS1) and rs953413 (ELOVL2) in InCHIANTI and GOLDN study.
InCHIANTI GOLDN
FADS: rs174537 G/G (n=569) T/G (n=414) T/T (n=92) P G/G (n=433) T/G (n=495) T/T (n=139) P
Linoleic acid 24.27 (3.99) 25.24 (3.98) 25.88 (3.69) ,0.0001 11.97 (0.15) 12.46 (0.14) 13.49 (0.17) ,0.0001
Eicosadienoic acid 0.12 (0.05) 0.11 (0.06) 0.09 (0.07) ,0.0001
Arachidonic acid 8.72 (1.86) 7.39 (1.51) 6.35 (1.36) ,0.0001 14.06 (0.09) 13.45 (0.09) 12.43 (0.12) ,0.0001
Alpha Linolenic acid 0.42 (0.24) 0.47 (0.26) 0.46 (0.22) ,0.0001 0.14 (0) 0.14 (0) 0.16 (0) ,0.0001
Eicosapentanoic acid 0.65 (0.24) 0.58 (0.18) 0.51 (0.16) ,0.0001 0.49 (0.02) 0.47 (0.02) 0.42 (0.03) ,0.0001
Docosapentanoic acid 1.97 (0.03) 1.93 (0.03) 1.83 (0.03) ,0.0001
Docosahexanoic acid 2.31 (0.77) 2.29 (0.76) 2.23 (0.77) 0.3188 3.28 (0.08) 3.22 (0.08) 3.13 (0.1) 0.0677
Triglyceride (mg/dL) 127.5 (84.2) 120.5 (61) 139.3 (100.4) 0.862 211 (18.7) 211.1 (19.8) 228.5 (31.6) 0.369
Total Cholesterol (mg/dL) 217 (40.9) 212.5 (40.2) 209.3 (40.4) 0.0268 202.5 (3.7) 194.2 (3.3) 194.4 (4.1) 0.0007
HDL Cholesterol (mg/dL) 55.8 (15.5) 56.2 (14.4) 54.6 (13.9) 0.7752 46.2 (1.3) 45.7 (1.3) 45.9 (1.4) 0.801
LDL Cholesterol (mg/dL) 135.6 (35.3) 132.2 (35) 126.9 (37.3) 0.0112 124.3 (3.2) 118.3 (2.9) 118 (3.2) 0.0093
ELOVL2: rs953413 G/G (n=343) A/G (n=520) A/A (n=211) G/G (n=344) A/G (n=527) A/A (n=190)
Eicosapentanoic acid 0.58 (0.25) 0.61 (0.18) 0.66 (0.22) ,0.0001 0.48 (0.02) 0.47 (0.03) 0.48 (0.03) 0.1817
Docosapentanoic acid 1.89 (0.03) 1.94 (0.03) 1.99 (0.03) 0.0007
Docosahexanoic acid 2.37 (0.79) 2.29 (0.75) 2.17 (0.74) 0.0044 3.32 (0.08) 3.2 (0.08) 3.1 (0.1) 0.0018
Values represent mean (SD).
Fatty acids are plasma concentrations (% total fatty acids) for InCHIANTI and erythrocytes concentration for GOLDN.
doi:10.1371/journal.pgen.1000338.t002
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In the InCHIANTI, dietary intake was assessed using a food-
frequency questionnaire (FFQ) created for the European Prospec-
tive Investigation into Cancer and nutrition (EPIC) study, and has
previously been validated to provide good estimates of dietary
intake in this study population [47,48] . In GOLDN, habitual
dietary intake was estimated using the validated dietary history
questionnaire (DHQ) developed by the National Cancer Institute
[49]. We excluded subjects that reported ,800 kcal and .5500
kcal in men and ,600kcal and .4500kcal in women.
Genotyping
InCHIANTI: Genome-wide genotyping was performed using the
Illumina Infinium HumanHap550 genotyping chip (chip version 1
and 3) as previously described [50]. The SNP quality control was
assessed using GAINQC. The exclusion criteria for SNPs were
minor allele frequency ,1% (n=25,422), genotyping complete-
ness ,99% (n=23,610) and Hardy Weinberg-equilibrium (HWE)
,0.0001 (n=517).
GOLDN: Five SNPs were selected for replication in the GOLDN
study: rs953413, rs2277324, rs16940765, rs17718324 and
rs174537. One of these, rs2277324, failed genotyping and
therefore another SNP in high LD, rs923838 (r
2=0.89 in
hapmap), was used as a proxy for this SNP. DNA was extracted
from blood samples and purified using commercial Puregene
reagents (Gentra System, Inc.) following manufacturer’s instruc-
tions. SNPs were genotyped using the 5’nuclease allelic discrim-
ination Taqman assay with allelic specific probes on the ABI Prism
7900HT Sequence Detection System (Applies Biosystems, Foster
City, Calif, USA) according to standard laboratory protocols. The
primers and probes were pre-designed (the assay -on -demand) by
the manufacturer (Applied Biosystem) (Assay ID: FEN_rs174537:
C___2269026_10, HRH4_rs16940765: C__32711739_10,
SPARC_rs17718324: C__34334455_10, ELOVL2_rs953413:
C___7617198_10, rs923828: C___2022671_10).
Statistical Analysis
InCHIANTI GWAS: Inverse normal transformation was applied
to plasma fatty acid concentrations to avoid inflated type I error
due to non-normality [51]. The genotypes were coded 0, 1 and 2
reflecting the number of copies of an allele being tested (additive
genetic model). For X-chromosome analysis, the average pheno-
type of males hemizygous for a particular allele was treated
assumed to match the average phenotype of females homozygous
for the same allele. Association analysis was conducted by fitting
simple regression test using the fastAssoc option in MERLIN [52].
Narrow heritability reflects the ratio of the trait’s additive variance
to the total variance [51,53]. In all the analyses, the models were
adjusted for sex, age and age squared. The genomic control
method was used to control for effects of population structure and
cryptic relatedness [54]. An approximate genome-wide signifi-
cance threshold of 1610
27 (,0.05/495343 SNPs) was used. For
each fatty acid concentration, a second analysis included the most
significant SNP from the first pass analysis as a covariate. Linkage
disequilibrium coefficints within the region of interest were
calculated using GOLD [55].
For the other phenotypes (total cholesterol, triglycerides, LDL-
cholesterol, HDL-cholesterol and BMI), the traits were normalized
either by natural log or square root transformation when
necessary. Associations for each SNP were investigated using the
general linear model (GLM) procedure in SAS.
GOLDN: Inverse normal transformation was applied to
erythrocyte membrane fatty acid concentration to achieve
approximate normality. For the additive model, genotype coding
was based on the number of variant alleles at the polymorphic site.
With no significant sex modification observed, men and women
were analyzed together. We used the generalized estimating
equation (GEE) linear regression with exchangeable correlation
structure as implemented in the GENMOD procedure in SAS
(Windows version 9.0, SAS Institute, Cary, NC) to adjust for
correlated observations due to familial relationships. Potential
confounding factors included study center, age, sex, BMI, smoking
(never, former and current smoker), alcohol consumption (non-
drinker and current drinker), physical activity, drugs for lowering
cholesterol, diabetes and hypertension and hormones. A two-tailed
P value of ,0.05 was considered to be statistically significant.
Supporting Information
Figure S1 Q-Q plots for (A) linolenic acid, (B) eicosadienoic acid
(C) arachidonic acid, (D), alpha-linolenic acid, (E), eicsapentanoic
acid, and (F) docsahexanoic acid from the first analysis (red circles)
and the second analysis after including the most significant SNP
(blue circles).
Found at: doi:10.1371/journal.pgen.1000338.s001 (0.52 MB TIF)
Figure S2 The associations in the fatty acid desaturase clusters
on chromosome 11 are displayed. (A) The 2log10 pvalues for
each fatty acid concentration within the FADS cluster on
chromosome 11. The y axis is truncated at 14, the most significant
SNP for arachidonic acid rs174537 at 2log10 value of 45. (B) The
genes that lie +/2 100kb of rs174537 and (C) pairwise LD (r
2)i n
the region ranging from high (red), intermediate (green), to low
(blue) in the InCHIANTI study.
Found at: doi:10.1371/journal.pgen.1000338.s002 (0.76 MB TIF)
Figure S3 The associations in the elongation of very long fatty
acid 2 gene are displayed. (A) The 2log10 pvalues for each fatty
acid concentration around the ELOVL2 gene. (B) The genes that
lie +/2 100kb of rs953413 and (C) pairwise LD (r
2) in the region
ranging from high (red), intermediate (green), to low (blue) in the
InCHIANTI study.
Found at: doi:10.1371/journal.pgen.1000338.s003 (0.53 MB TIF)
Table S1 Top 10 non-redundant SNPs for each plasma fatty
acid concentrations.
Found at: doi:10.1371/journal.pgen.1000338.s004 (0.15 MB
DOC)
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